APO-Pemetrexed pemetrexed 500 mg (as disodium) powder for injection vial

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

pemetrexed disodium hemipentahydrate, Quantity: 604 mg (Equivalent: pemetrexed, Qty 500 mg)

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

Designación común internacional (DCI):

pemetrexed disodium hemipentahydrate

formulario farmacéutico:

Injection, powder for

Composición:

Excipient Ingredients: sodium hydroxide; hydrochloric acid; mannitol

Vía de administración:

Intravenous Infusion

Unidades en paquete:

1

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell Lung Cancer (NSCLC),Pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology.,Pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Resumen del producto:

Visual Identification: White to either light yellow or green-yellow powder.; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Estado de Autorización:

Registered

Fecha de autorización:

2014-09-04